FDA approves Genentech's Gazyva for primary membranous nephropathy
The FDA approved Genentech’s Gazyva as the first treatment for adults with primary membranous nephropathy at risk of disease progression. At two years, complete proteinuria remission occurred in 36.1% of patients receiving Gazyva, compared with 5.7% receiving tacrolimus.
1. FDA approval
The FDA approved Genentech’s Gazyva as the first treatment for adults with primary membranous nephropathy at risk of disease progression. Phase III results showed complete proteinuria remission at two years in 36.1% of Gazyva patients versus 5.7% of patients receiving tacrolimus.





